Anogen-Yes Biotech

04/29/2026

The latest Antibodies to Watch 2026 report highlights the rapid expansion of antibody-based therapeutics:

✔ 19 new antibody approvals in 2025
✔ 200+ molecules in late-stage development
✔ Increasing adoption of advanced formats such as ADCs and bispecific antibodies

One of the most notable trends is the global shift in innovation. Over 50% of newly approved antibodies in 2025 originated from China, reflecting a rapidly evolving and competitive landscape.

With an average development timeline of ~6 years—and even faster in some regions—the pace of innovation in antibody therapeutics continues to accelerate.

As the field advances, reliable tools for antibody characterization, biomarker analysis, and immunoassay development remain essential to support this growth.

Read the full article here: https://www.tandfonline.com/doi/full/10.1080/19420862.2026.2614669

The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics. Since the first ar...

04/22/2026

A recent publication from Tiziana Life Sciences highlights the potential of intranasal anti-CD3 therapy (foralumab) in modulating immune responses.

This innovative approach:

✔ Targets immune balance rather than broad suppression

✔ Utilizes a non-invasive intranasal delivery method

✔ Shows promise in addressing neuroinflammatory and autoimmune conditions

As research continues, therapies like this may open new pathways for treating complex CNS disorders, including Alzheimer’s and multiple sclerosis.

At Anogen, we support advancing immunology research with reliable tools for cytokine and immune profiling.

🔗 Read more: https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-announces-publication-110000819.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJKA8oHHKhd7J78oW3jheEu-Y2RkdmpjazN5qJPYuUK5pVrwTHjM17f0eMBx2jojlLCOP_n8mRfbi4Rmlc6HSlOtfl9yOo0n2NxUNXrWrK3ccwDN2nqHiORyDgs8yJ3qflWnNdhvERieMNBcNkVU97WtUGbzUql2RTs5dBVAZPfy

-T

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”)...

04/22/2026

A recent publication from Tiziana Life Sciences highlights the potential of intranasal anti-CD3 therapy (foralumab) in modulating immune responses.

This innovative approach:

✔ Targets immune balance rather than broad suppression

✔ Utilizes a non-invasive intranasal delivery method

✔ Shows promise in addressing neuroinflammatory and autoimmune conditions

As research continues, therapies like this may open new pathways for treating complex CNS disorders, including Alzheimer’s and multiple sclerosis.

At Anogen, we support advancing immunology research with reliable tools for cytokine and immune profiling.

🔗 Read more: https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-announces-publication-110000819.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJKA8oHHKhd7J78oW3jheEu-Y2RkdmpjazN5qJPYuUK5pVrwTHjM17f0eMBx2jojlLCOP_n8mRfbi4Rmlc6HSlOtfl9yOo0n2NxUNXrWrK3ccwDN2nqHiORyDgs8yJ3qflWnNdhvERieMNBcNkVU97WtUGbzUql2RTs5dBVAZPfy

-T

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”)...

04/15/2026

🧠 Could intranasal immunotherapy help improve cognition associated with aging?

Recent data from Tiziana Life Sciences highlights the potential of nasal anti-CD3 therapy (foralumab) in modulating immune responses linked to neuroinflammation and cognitive decline.

Key takeaways:
• Intranasal anti-CD3 showed improvement in cognition associated with aging
• Mechanism involves induction of regulatory T cells (Tregs)
• Reduced neuroinflammation without broad systemic immunosuppression
• Represents a novel, non-invasive approach to targeting CNS immune pathways

This research points toward an emerging strategy—immune modulation via mucosal tolerance—as a potential avenue for treating neurodegenerative conditions and age-related cognitive decline.

📌 Read the full article: https://www.nasdaq.com/press-release/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-aging

04/08/2026

Recent research highlights the potential of intranasal anti-CD3 therapy (foralumab) in patients with non-active secondary progressive multiple sclerosis (na-SPMS).

In a small open-label study:
• Patients showed disease stabilization, with some improvement
• No serious treatment-related adverse events were reported
• Imaging revealed reduced neuroinflammation
• Immune profiling suggested increased regulatory T cell activity

Unlike traditional therapies, this approach uses intranasal delivery to modulate the immune system—potentially reducing neuroinflammation without broad immunosuppression.

While further studies are ongoing, these findings offer a promising direction for addressing progression independent of relapse activity (PIRA), a key challenge in MS treatment.

📌 Based on recently published research in a peer-reviewed neurology journal.
https://www.globenewswire.com/news-release/2026/02/25/3244474/0/en/Tiziana-Life-Sciences-Announces-New-Biomarker-Data-Showing-Nasal-Foralumab-Downregulates-CSF-Inflammation-Upregulates-Neuroprotective-Pathways-and-Correlates-with-Reduced-Microglia.html

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate,...

04/01/2026

🧠 Understanding Tau Protein and Its Role in Alzheimer’s Disease
Tau protein is a key structural component found in neurons, where it helps stabilize microtubules and supports normal cell function. However, in neurodegenerative conditions such as Alzheimer’s disease, tau can become abnormal.

When tau proteins undergo changes (such as hyperphosphorylation), they may detach from microtubules and form aggregates known as neurofibrillary tangles. These tangles disrupt communication between neurons and are strongly associated with cognitive decline.

🔬 In research and diagnostics, tau has become an important biomarker. Scientists are actively exploring:

• How tau interacts with beta-amyloid
• Methods to detect tau (e.g., PET imaging, cerebrospinal fluid, and emerging blood-based markers)
• Therapeutic strategies targeting tau accumulation

While there is currently no cure for Alzheimer’s disease, ongoing research into tau biology continues to advance our understanding of disease mechanisms and potential treatments.

At Anogen, we support neuroscience research by providing recombinant proteins and antibodies related to key biomarkers such as tau.

03/18/2026

We’re proud to share that our Mouse Interleukin-1β (IL-1β) ELISA Kit (MEC1010) played a key role in a groundbreaking study published in Nature Communications. This research, led by Shen Liu and team from Shanghai Jiao Tong University, focuses on neuromorphic electro-stimulation using atomically thin semiconductors for damage-free inflammation inhibition.

Read the full article here: https://lnkd.in/epEgahau

Our IL-1β ELISA Kit was used in this study to measure cytokine levels, providing valuable insights into inflammation control at the molecular level. This product is perfect for immunology and inflammation studies and is backed by high accuracy and reliability.

Interested in exploring how our products can enhance your research? Check out our Mouse IL-1β ELISA Kit here and see how we can support your scientific breakthroughs! https://lnkd.in/ewYnsCw4

03/11/2026

A new study from Washington University School of Medicine reports encouraging evidence that anti-amyloid treatment given before symptoms appear may help delay or prevent Alzheimer’s dementia.

Key insights from the research:

🔬 Anti-amyloid therapy significantly reduced amyloid-β plaque accumulation in the brain

🧬 Participants treated before cognitive symptoms showed signs of delayed disease onset

📊 Biomarkers such as amyloid and tau measurements remain critical tools for early detection and monitoring treatment response

These findings reinforce the importance of early diagnosis and targeted therapies in the fight against Alzheimer’s disease.

Read more:
https://medicine.washu.edu/news/anti-amyloid-drug-shows-signs-of-preventing-alzheimers-dementia/

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies

03/04/2026

A recent article in Biomedical Research and Therapy explores the role of amyloid-β plaques and tau neurofibrillary tangles in Alzheimer’s disease and the therapeutic strategies targeting these pathologies.

Key takeaways:

🔬 Alzheimer’s pathology is driven by the accumulation of Aβ plaques and hyperphosphorylated tau proteins, which together accelerate neuronal damage.

💊 Emerging therapies include monoclonal antibodies targeting Aβ and tau, aiming to slow disease progression and promote immune-mediated clearance.

🚀 Advanced delivery technologies such as nanoparticle-based systems and exosome carriers may improve brain targeting and treatment efficacy.

Understanding the interaction between Aβ and tau remains critical for developing next-generation treatments for Alzheimer’s disease.

Read the article:

https://bmrat.org/index.php/BMRAT/article/view/1004

Review Amyloid Beta and Tau Aggregation: The Etiology and Potential Pharmaceutical Approaches for Alzheimer’s Disease Pushpendra Soni 1 Syed Misbahul Hasan 1 Shom Prakash Kushwaha 1, * Kuldeep Singh 1 Arun Kumar 1 Abdul Hafeez 1 Suvaiv 1 Samman 1 Salman Khan 1 Google Scholar PubMed Faculty of Phar...

02/25/2026

New poster data presented at CTAD highlight promising biomarker effects of etalanetug, a tau-targeting immunotherapy. In patients with dominantly inherited Alzheimer’s disease, treatment was associated with reductions in key tau pathology biomarkers in CSF—providing evidence of target engagement and potential disease-modifying activity.

Although further studies are needed to determine clinical impact, these findings reinforce the growing momentum behind tau-directed therapeutic strategies in neurodegenerative disease.

Read the full article: https://www.neurologylive.com/view/ctad-poster-etalanetug-reduces-tau-pathology-biomarkers-dominantly-inherited-ad

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

02/18/2026

A study published in Biology Direct reveals how hypoxia influences microglia and promotes glioma growth through inflammatory cytokine secretion.
Researchers used Anogen’s Multiplex Human Cytokine ELISA Kit (EM10001) to measure cytokines like IL-1β, IL-6, TNF-α, and more, uncovering how IL-1β–NF-κB–heparanase signaling drives tumor progression in glioma.

Anogen is proud to support cancer research with trusted ELISA kits and antibodies.
Learn more: www.anogen.ca

https://www.youtube.com/watch?v=9tCdiFlMWmc

🧠 TREM2 & Inflammation: New Insights into Alzheimer’s DiseaseA recent study highlights the key role of TREM2 in regulating inflammatory responses in macroph...

02/11/2026

A small open-label clinical trial in individuals with dominantly inherited Alzheimer’s disease (DIAD) suggests that tau immunotherapy may significantly reduce tau-related biomarkers in both cerebrospinal fluid (CSF) and plasma.

After treatment, levels of phosphorylated tau and other tangle-associated markers declined noticeably, indicating that the antibody therapy may be engaging its intended target and affecting tau pathology biology. While the study was small and not placebo-controlled, the biomarker reductions provide encouraging biological evidence that anti-tau immunotherapy can alter disease-related processes.

Researchers emphasized that larger, controlled trials are still needed to determine whether these biomarker changes translate into meaningful clinical benefit.

Read the full article: https://www.alzforum.org/news/conference-coverage/after-tau-immunotherapy-tangle-markers-tank-csf-plasma #:~:text=In%20a%20small%2C%20open%2Dlabel%20trial%20in%20people,inherited%20Alzheimer's%20disease%20(DIAD)%2C%20the%20tau%20immunotherapy

After Tau Immunotherapy, Tangle Markers Tank in CSF, Plasma Go to another part Series - Clinical Trials on Alzheimer's Disease (CTAD) 2025: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn Back...